Mark E.  Dmytruk net worth and biography

Mark Dmytruk Biography and Net Worth

Insider of Ginkgo Bioworks
Mark joined Ginkgo in November 2020 with 25 years of finance and executive leadership experience, primarily in the life sciences and diagnostics industries. Prior to Ginkgo, Mark held several executive roles at Syneos Health (formerly INCResearch / inVentiv Health), a $4.5B revenue global CRO serving the biopharma industry, including EVP Corporate Strategy & Development and President, Patient Outcomes division. Prior to Syneos, Mark was at Thermo Fisher Scientific from 2001 - 2011. As VP Corporate Development, Mark led the company’s M&A function, contributing to its industry-changing strategy and transformational growth. He was also VP Finance for the Athena Diagnostics business unit prior to its sale to Quest Diagnostics. Mark began his career at Ernst & Young in Canada. He holds a Bachelor of Commerce from the University of Alberta and an MBA from the Sloan School of Management at MIT.

What is Mark E. Dmytruk's net worth?

The estimated net worth of Mark E. Dmytruk is at least $9.46 million as of May 2nd, 2024. Mr. Dmytruk owns 925,400 shares of Ginkgo Bioworks stock worth more than $9,457,588 as of December 26th. This net worth evaluation does not reflect any other assets that Mr. Dmytruk may own. Additionally, Mr. Dmytruk receives a salary of $476,500.00 as Insider at Ginkgo Bioworks. Learn More about Mark E. Dmytruk's net worth.

How old is Mark E. Dmytruk?

Mr. Dmytruk is currently 52 years old. There are 2 older executives and no younger executives at Ginkgo Bioworks. Learn More on Mark E. Dmytruk's age.

What is Mark E. Dmytruk's salary?

As the Insider of Ginkgo Bioworks Holdings, Inc., Mr. Dmytruk earns $476,500.00 per year. Learn More on Mark E. Dmytruk's salary.

How do I contact Mark E. Dmytruk?

The corporate mailing address for Mr. Dmytruk and other Ginkgo Bioworks executives is 955 Fifth Avenue, New York NY, 10075. Ginkgo Bioworks can also be reached via phone at 877-442-5362 and via email at [email protected]. Learn More on Mark E. Dmytruk's contact information.

Has Mark E. Dmytruk been buying or selling shares of Ginkgo Bioworks?

Mark E. Dmytruk has not been actively trading shares of Ginkgo Bioworks during the last ninety days. Most recently, Mark E. Dmytruk sold 47,806 shares of the business's stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $0.84, for a transaction totalling $40,157.04. Following the completion of the sale, the insider now directly owns 925,400 shares of the company's stock, valued at $777,336. Learn More on Mark E. Dmytruk's trading history.

Who are Ginkgo Bioworks' active insiders?

Ginkgo Bioworks' insider roster includes Barry Canton (Major Shareholder), Marijn Dekkers (Director), Mark Dmytruk (Insider), Christian Henry (Director), Jason Kelly (Insider), Reshma Shetty (Insider), and Harry Sloan (Director). Learn More on Ginkgo Bioworks' active insiders.

Are insiders buying or selling shares of Ginkgo Bioworks?

In the last twelve months, Ginkgo Bioworks insiders bought shares 1 times. They purchased a total of 297,619 shares worth more than $270,833.29. In the last twelve months, insiders at the sold shares 10 times. They sold a total of 548,626 shares worth more than $538,373.82. The most recent insider tranaction occured on December, 4th when insider Steven P Coen sold 330 shares worth more than $3,181.20. Insiders at Ginkgo Bioworks own 9.7% of the company. Learn More about insider trades at Ginkgo Bioworks.

Information on this page was last updated on 12/4/2024.

Mark E. Dmytruk Insider Trading History at Ginkgo Bioworks

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/2/2024Sell47,806$0.84$40,157.04925,400View SEC Filing Icon  
4/2/2024Sell51,169$1.05$53,727.45865,079View SEC Filing Icon  
2/2/2024Sell39,569$1.21$47,878.49761,737View SEC Filing Icon  
12/4/2023Sell42,402$1.39$58,938.78676,844View SEC Filing Icon  
10/2/2023Sell42,237$1.76$74,337.12586,393View SEC Filing Icon  
9/5/2023Sell41,417$2.23$92,359.91543,585View SEC Filing Icon  
8/2/2023Sell46,519$2.07$96,294.33499,959View SEC Filing Icon  
7/3/2023Sell40,637$1.80$73,146.60461,432View SEC Filing Icon  
6/2/2023Sell40,511$1.56$63,197.16417,028View SEC Filing Icon  
5/22/2023Sell250,000$1.50$375,000.00372,495View SEC Filing Icon  
4/10/2023Sell740$1.33$984.20576,254View SEC Filing Icon  
3/15/2023Sell29,762$1.31$38,988.22530,736View SEC Filing Icon  
1/4/2023Sell34,588$1.56$53,957.28454,549View SEC Filing Icon  
11/3/2022Sell30,604$2.65$81,100.60384,074View SEC Filing Icon  
See Full Table

Mark E. Dmytruk Buying and Selling Activity at Ginkgo Bioworks

This chart shows Mark E Dmytruk's buying and selling at Ginkgo Bioworks by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ginkgo Bioworks Company Overview

Ginkgo Bioworks logo
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $10.22
Low: $8.92
High: $10.48

50 Day Range

MA: $8.66
Low: $6.33
High: $11.66

2 Week Range

Now: $10.22
Low: $5.26
High: $74.00

Volume

1,105,193 shs

Average Volume

1,175,909 shs

Market Capitalization

$587.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17